Craig F Teller MD FAAD

Clinical Trials

• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Start of enrollment: 2019 Aug 12

  Active, not recruiting

  Phase 3

• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) Start of enrollment: 2020 Jun 15

  ACTIVE_NOT_RECRUITING

  PHASE3

• A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema) Start of enrollment: 2015 Mar 31

  Completed

  Phase 2

• Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2013 May 01

  Completed

  Phase 2

• Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) Start of enrollment: 2013 Dec 31

  Completed

  Phase 2

• Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2018 Nov 12

  Terminated

  Phase 2

• Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2019 Jul 01

  Active, not recruiting

• A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2019 May 13

  Completed

  Phase 3

• Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2014 Nov 20

  Completed

  Phase 2

• Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa Start of enrollment: 2022 Apr 25

  Completed

  Phase 2

• Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) Start of enrollment: 2019 Feb 25

  COMPLETED

  PHASE3

• A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) Start of enrollment: 2018 Jul 27

  Active, not recruiting

  Phase 3

• Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo Start of enrollment: 2021 Jun 30

  COMPLETED

  PHASE2

• A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Start of enrollment: 2019 Jul 08

  COMPLETED

  PHASE3

• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Start of enrollment: 2018 Sep 24

  ACTIVE_NOT_RECRUITING

  PHASE2, PHASE3

• Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Start of enrollment: 2012 Sep 01

  Terminated

  Phase 3

• Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition Start of enrollment: 2018 Nov 12

  Completed

  Phase 3

• Restylane Volyme for Correction of Midface Volume Deficit and/or Midface Contour Deficiency Start of enrollment: 2017 Dec 01

  Completed

  Not Applicable

• Join now to see all